Stock Fundamentals

Company Information

Company Name
Arvinas Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04335A1051
CIK: 0001655759
CUSIP: 04335A105
Currency: USD
Full Time Employees: 246
Phone: 203 535 1456
Fiscal Year End: December
IPO Date: Sep 27, 2018
Description:

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Address:

5 Science Park, New Haven, CT, United States, 06511

Directors & Officers

Name Title Year Born
Mr. Andrew R. Saik CFO & Treasurer 1969
Ms. Angela M. Cacace Ph.D. Chief Scientific Officer 1968
Dr. Noah Berkowitz M.D., Ph.D. Chief Medical Officer 1964
Dr. Randy Teel Ph.D. CEO, President & Director 1980
Mr. David K. Loomis M.B.A. VP & Chief Accounting Officer 1974
Mr. Jeff Boyle Vice President of Investor Relations NA
Mr. Jared M. Freedberg J.D. General Counsel & Corporate Secretary 1969
Mr. Steve Weiss Senior VP & Chief Human Resources Officer 1970
Mr. Paul McInulty Senior Vice President of Regulatory Affairs NA
Mr. Alexander A. Santini Chief Commercial Officer 1959

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 18, 2026 Noah Berkowitz N/A Sale 6.44K $11.10 $71.43K
Mar 06, 2026 Briggs Morrison N/A Purchase 20.00K $13.40 $268.00K
Feb 27, 2026 John G Houston N/A Sale 35.30K $13.21 $466.27K
Feb 23, 2026 David K Loomis N/A Sale 1.11K $12.16 $13.47K
Feb 23, 2026 Randy Teel N/A Sale 4.79K $12.16 $58.20K
Feb 13, 2026 Andrew Saik N/A Sale 5.13K $11.89 $61.04K
Feb 13, 2026 David K Loomis N/A Sale 1.02K $11.89 $12.08K
Feb 13, 2026 Noah Berkowitz N/A Sale 5.69K $11.89 $67.59K
Feb 13, 2026 Randy Teel N/A Sale 4.40K $11.89 $52.35K
Nov 07, 2025 David K Loomis N/A Sale 230.00 $9.89 $2.27K
Sep 22, 2025 Briggs Morrison N/A Purchase 30.00K $7.57 $227.10K
Jun 24, 2025 Andrew Saik N/A Sale 5.70K $7.61 $43.38K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 7.23M Dec 31, 2025 11.21% $0.00 -15.55%
BlackRock Inc 6.80M Mar 31, 2026 10.54% $0.00 -7.17%
Vanguard Portfolio Management, LLC 3.89M Mar 31, 2026 6.03% $0.00 0.00%
D. E. Shaw & Co LP 3.64M Mar 31, 2026 5.64% $0.02 -1.37%
Pfizer Inc 3.46M Mar 31, 2026 5.36% $14.63 0.00%
Vanguard Capital Management, LLC 2.69M Mar 31, 2026 4.17% $0.00 0.00%
TCG Crossover Management, LLC 2.39M Mar 31, 2026 3.70% $0.72 -10.46%
Armistice Capital, LLC 1.98M Mar 31, 2026 3.07% $0.37 9.89%
Two Sigma Investments LLC 1.83M Mar 31, 2026 2.84% $0.02 84.60%
State Street Corp 1.83M Mar 31, 2026 2.83% $0.00 -0.81%
Geode Capital Management, LLC 1.56M Mar 31, 2026 2.41% $0.00 -4.09%
Jacobs Levy Equity Management, Inc. 1.44M Mar 31, 2026 2.23% $0.06 471.37%
Qube Research & Technologies 1.20M Mar 31, 2026 1.86% $0.01 -9.29%
Citadel Advisors Llc 1.18M Mar 31, 2026 1.83% $0.00 185.51%
Federated Hermes Inc 1.14M Mar 31, 2026 1.77% $0.02 4.18%
Acadian Asset Management LLC 949.87K Mar 31, 2026 1.47% $0.01 2,642.45%
Vestal Point Capital LP 905.47K Mar 31, 2026 1.40% $0.27 0.00%
The Goldman Sachs Group Inc 756.88K Mar 31, 2026 1.17% $0.00 -32.19%
Morgan Stanley - Brokerage Accounts 674.72K Mar 31, 2026 1.05% $0.00 -16.71%
Two Sigma Advisers, LLC 619.90K Dec 31, 2025 0.96% $0.01 4,705.43%

Shares Statistics

Shares Outstanding: 64.52M
Shares Float: 55.95M
% Insiders: 776.30%
% Institutions: 8,328.40%
Short % Float: 8.52%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.92M 2.98% ▲ 0.00% Apr 30, 2026
2 Vanguard Strategic Equity Inv 1.62M 2.51% ▲ 0.00% Mar 31, 2026
3 iShares Russell 2000 ETF 1.33M 2.06% ▲ 0.93% May 29, 2026
4 Vanguard Explorer Inv 896.37K 1.39% ▼ 12.24% Mar 31, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 723.42K 1.12% ▲ 1.61% Apr 30, 2026
6 Fidelity Small Cap Index 546.16K 0.85% ▼ 15.07% Mar 31, 2026
7 BlackRock Advantage Small Cap Core Instl 529.73K 0.82% ▲ 48.20% Apr 30, 2026
8 Vanguard Strategic Small-Cap Equity Inv 488.69K 0.76% ▲ 0.00% Mar 31, 2026
9 Federated Hermes MDT Small Cap Core IS 429.22K 0.67% ▲ 0.00% Mar 31, 2026
10 Federated Hermes MDT SCC Institutional 429.22K 0.67% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $-118.40M
Trailing P/E: 0.00
Forward P/E: 17.86

Financial Highlights

Market Cap: $489.07M
EBITDA: $-246.50M
Book Value: $6.00
Earnings/Share: $-3.18
Profit Margin: -247.54%
Operating Margin: -405.13%
ROA (TTM): -18.92%
ROE (TTM): -42.28%
Revenue (TTM): $89.40M
Revenue/Share (TTM): $1.30
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -91.70%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.92x 0.00x 0.40x N/A -0.03x
2024-12-31 4.64x 0.00x 0.49x N/A -0.01x
2023-12-31 4.98x 0.00x 0.49x N/A -0.01x
2022-12-31 4.20x 0.00x 0.55x -21.93x -0.01x
2021-12-31 5.93x 0.00x 0.51x -1,953.00x -0.01x
2020-12-31 14.29x 0.00x 0.10x -1,920.88x -0.02x
2019-12-31 8.86x 0.01x 0.25x -602.14x -0.05x
2018-12-31 8.52x 0.02x 0.31x -762.57x -0.05x
2017-12-31 3.67x 1.26x 1.00x -491.69x -0.01x
2016-12-31 3.72x 0.02x 0.37x -244.34x -0.03x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ARVN.US!